Management of Acute Decompensated Heart Failure
Initial Treatment
- The American Heart Association recommends adding a loop diuretic, such as furosemide 20-40 mg orally, immediately to relieve congestion, and initiating a beta-blocker at low dose once symptoms stabilize, as this patient is critically undertreated with guideline-directed medical therapy despite having nonischemic cardiomyopathy 1, 2
- The European Society of Cardiology suggests that beta-blockers provide early and striking reduction in overall mortality and are particularly effective in reducing sudden cardiac death, and should be started once the patient is stabilized on diuretics, not delayed until "optimal" medical therapy is achieved 3, 5
Medication Management
- The American College of Cardiology recommends that beta-blockers should be started at a low dose, with options including carvedilol 3.125 mg twice daily, metoprolol succinate 12.5-25 mg daily, or bisoprolol 1.25 mg daily, and uptitrated over 8-12 weeks as tolerated, monitoring blood pressure, heart rate, potassium, and creatinine 1, 2, 6
- The European Heart Journal suggests that mineralocorticoid receptor antagonists, such as spironolactone 12.5-25 mg daily, should be added for patients with NYHA class II-IV symptoms despite ACE inhibitor therapy, and can reduce mortality and HF hospitalization by 30% when added to ACE inhibitor and beta-blocker 1, 2, 4, 6
Special Considerations
- The European Society of Cardiology recommends that cardiac resynchronization therapy (CRT) is a Class I recommendation if LVEF ≤35% persists after 3 months of optimal GDMT, and can improve symptoms, survival, and reduce morbidity in symptomatic HF patients with sinus rhythm, LVEF ≤35%, and LBBB morphology with QRS ≥150 ms 1, 4, 5
- The American Heart Association suggests that guideline-directed medical therapy, including RAAS inhibition and beta-blockers, improves secondary MR and LV dimensions in HFrEF patients, and sacubitril-valsartan (ARNi) may provide additional benefit for MR reduction compared to ACE inhibitors alone 1, 2
Monitoring Parameters
- The European Heart Journal recommends weekly monitoring for the first month, including blood pressure and heart rate, daily weights, and symptoms, and laboratory monitoring, including potassium and creatinine, 5-7 days after each medication change, then monthly for 3 months, and then every 3-6 months once stable 2, 4, 6
- The American College of Cardiology suggests that LVEF should be reassessed in 3 months to determine need for ICD or CRT 1, 2